A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Inclusion Criteria: * Male or female aged ≥ 12 years and weighing ≥ 40 kg at the time of ICF signature; * Patients with HoFH who meet genetic or clinical diagnosis; * Willing to follow a daily low-fat diet for the duration of the study; * Receiving stable and tolerable lipid-lowering therapy prior to LDL-C testing during the screening period; * Fasting LDL-C ≥ 2.6 mmol/L. Exclusion Criteria: * Have received or are receiving targeted ANGPTL3 treatment within 5 months or 5 half-lives, whichever is longer, prior to screening; * Fasting TG ≥ 4.5 mmol/L at screening; * Presence of uncontrolled endocrine disease affecting lipids or lipoproteins; * Weight change of more than 10% in the 4 weeks prior to randomisation; * Initiation of a new dietary plan or significant differences from previous dietary structure and habits within 4 weeks prior to screening; * Women who are pregnant (including planned pregnancies) or breastfeeding; * Refusal to limit alcohol consumption to moderate limits and below during the study period, specifically no more than 14 units per week; * Uncontrolled hypertension (blood pressure \> 160/100 mmHg at screening); * New York Heart Association (NYHA) class IV heart failure or left ventricular ejection fraction \<30% within 12 months prior to screening; * History of major surgery within 12 weeks prior to baseline, or planning to undergo major surgery during the study; * Known allergy to any component of the study drug.